Agency spends N3bn for anti-retroviral drugs annually in Abuja

(Last Updated On: 2017-05-26)


The Federal Capital Territory (FCT) Agency for Control of HIV/AIDS (FACA) says it expends about N3 billion annually on Anti-Retroviral drugs (ARV) for HIV patients in the territory.

The Project Manager of the agency, Dr Uche Okoro, made this known to the News Agency of Nigeria (NAN) on Thursday in Abuja.

Okoro explained that about 60,000 people living with HIV were receiving ARV in FCT and N50,000 was spent on each of them per annum.

He said that the FCT had a total of 100,000 patients that were accessing care in various centres pointing out that with new policy on test and treat, other persons living with disease would be added to 60,000 receiving anti-retroviral drugs.

According to him, there used to observed some procedures before a patient could be enlisted among those taking ARV but henceforth all HIV patients under the agency’s care would be receiving anti-retroviral drugs.

The project manager also disclosed that majority of these patients were on first line drugs, while very few of them were receiving second and third line drugs which were more expensive and scarce than first line drugs.

He regretted gradual withdrawal of support by some development partners, saying that government had no choice than to take ownership of the programme.

He noted that people living with HIV were accessing their drugs in 134 centres while 230 centres conduct testing and counselling across the territory.

Okoro said that the agency had scaled up their reach and expanded it to get to so many people living with the disease in FCT.


How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Ad 2


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.